An Open-label Randomized Multi-center Phase III Study of TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer

Trial Profile

An Open-label Randomized Multi-center Phase III Study of TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs Gimeracil/oteracil/tegafur/folinic acid (Primary) ; Cisplatin; Oxaliplatin
  • Indications Gastric cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms SOLAR
  • Sponsors Taiho Pharmaceutical
  • Most Recent Events

    • 02 Aug 2017 Planned End Date changed from 1 May 2018 to 1 May 2019.
    • 02 Aug 2017 Planned primary completion date changed from 1 May 2018 to 1 May 2019.
    • 15 Feb 2017 Planned primary completion date changed from 1 Mar 2018 to 1 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top